orticumab
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2021 (NCT04776629)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
OLR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06927739 | Phase 2 | Aug 11, 2025 | Abcentra |
| NCT04776629 | Phase 2 | Jun 30, 2021 | Abcentra, Orange County Research Center |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abcentra | For profit | 2 | 2 | 1 | 2021 |
| Orange County Research Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1